Original Article
Brief Report
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
N Engl J Med 2009; 361:1173-1178September 17, 2009
- Abstract
Medulloblastoma is the most common malignant brain tumor in children. Aberrant activation of the hedgehog signaling pathway is strongly implicated in the development of some cases of medulloblastoma. A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms. Molecular analyses of tumor specimens obtained before treatment suggested that there was activation of the hedgehog pathway, with loss of heterozygosity and somatic mutation of the gene encoding patched homologue 1 (PTCH1), a key negative regulator of hedgehog signaling.
Media in This Article
Figure 1
Tumor Response on Positron-Emission Tomographic (PET) Scanning.Figure 2
Tumor-Specific Hedgehog Pathway Activation.Article Activity
- Article
Medulloblastoma is a malignant tumor of the cerebellum. The median age at diagnosis is 5 years, with the age range extending into young adulthood. Primary management consists of surgical resection followed by radiation therapy and chemotherapy. Current therapies have serious short-term and long-term adverse effects, including postoperative mutism, neurocognitive deficits, endocrinopathies, sterility, and the risk of secondary high-grade glioma or meningioma.1 Patients with recurrent disease after primary therapy have a particularly poor prognosis, with a median survival of less than 6 months; the 2-year survival rate among these patients is approximately 9%.2
The hedgehog pathway is an essential embryonic signaling cascade that regulates stem-cell and progenitor-cell differentiation in multiple developmental processes.3 Smoothened homologue (SMO) is a transmembrane protein that activates the downstream hedgehog signaling pathway. PTCH1 is an inhibitory cell-surface receptor that constitutively suppresses activation of the hedgehog pathway by inhibiting SMO. Hedgehog ligands bind to and inactivate PTCH1, derepressing SMO and promoting pathway activation.
Medulloblastoma is thought to arise from stem cells or early progenitor cells in the cerebellum.4 A critical developmental process in cerebellar maturation involves expansion, migration, and differentiation of immature precursor cells from the external granule-cell layer to form the internal granule-cell layer.5 This process is spatially and temporally regulated by activation of the hedgehog pathway in granule-cell precursors.6
Both preclinical and clinical observations suggest that aberrant ligand-independent constitutive activation of the hedgehog signaling pathway in granule-cell precursors promotes the development of medulloblastoma. Heterozygous deletion of the murine homologue of PTCH1 (Ptc1) results in medulloblastoma in approximately one third of mice by 25 weeks of age.7 Granule-cell precursors in the external granule-cell layer give rise to these tumors, which are associated with loss or mutation of the remaining wild-type Ptc1 allele.8 Inhibition of the hedgehog pathway by SMO inhibitors such as cyclopamine and HhAntag result in regression of medulloblastoma tumors in Ptc1 +/− mice.9,10 Constitutive activation of hedgehog signaling — often due to inactivating mutations of PTCH1 — has been shown in approximately 30% of medulloblastomas in humans.11 Medulloblastoma develops in approximately 5% of patients with nevoid basal-cell carcinoma syndrome (Gorlin's syndrome), an autosomal dominant disorder of germ-line PTCH mutations.12
GDC-0449 is an orally bioavailable selective inhibitor of SMO (Figure 1A in the Supplementary Appendix, available with the full text of this article at NEJM.org). GDC-0449 induces rapid regression of the tumor and suppression of the hedgehog pathway in the Ptc1 +/− murine medulloblastoma model (Figure 1B and 1C in the Supplementary Appendix).
Preliminary pharmacokinetic, safety, and efficacy data from our ongoing phase 1 clinical trial of daily administration of GDC-0449 in patients with advanced solid tumors have been presented recently.13 Initial results suggest that this agent has an acceptable side-effect profile at doses that lead to steady-state concentrations above those predicted to have efficacy in preclinical models. Preliminary efficacy was seen in patients with advanced basal-cell carcinoma, another type of tumor that is known to harbor PTCH1 mutations.14 The highest dose level of GDC-0449 used in this trial was 540 mg per day.
Case Report
The patient was a 26-year-old man who received the diagnosis of medulloblastoma confined to the cerebellum in 2004, when he was 22 years of age. Initial therapy included gross total resection and adjuvant craniospinal irradiation followed by the administration of carboplatin, etoposide, cyclophosphamide, and vincristine. Recurrent and metastatic disease was confirmed by means of a biopsy 2 years after the initial diagnosis, and the patient was treated with induction etoposide, temozolomide, and cyclophosphamide. After a partial response was achieved, he underwent autologous stem-cell transplantation. Eighteen months later, widespread systemic metastatic disease developed without a recurrence in the central nervous system. The patient underwent two surgeries and two radiosurgical procedures for the management of epidural intraspinal metastatic medulloblastoma. Additional systemic therapies in 2008 included temozolomide, which was discontinued owing to refractory thrombocytopenia, and bevacizumab, which the patient received in March and April of 2008 and which was subsequently discontinued owing to progression of the disease in the context of worsening pancytopenia.
The patient was evaluated in April 2008. He reported diffuse pain in his bones (the severity of which he rated as 5 on a scale of 0 to 10, with higher numbers indicating more severe pain), despite the administration of up to 640 mg of oxycodone daily. On physical examination, the patient was observed to be a thin man with palpable left supraclavicular lymphadenopathy and indurated masses protruding from the sternum. Laboratory findings were notable for pancytopenia (total white cells, 1750 per cubic millimeter; hemoglobin level, 9.7 g per deciliter; and platelets, 14,000 per cubic millimeter). He required transfusions of platelets twice a week and transfusions of packed red cells approximately once a week. A combined positron-emission tomographic (PET) and computed tomographic (CT) scan revealed extensive skeletal and soft-tissue metastases (Figure 1AFigure 1
Tumor Response on Positron-Emission Tomographic (PET) Scanning.).The patient was referred for consideration of enrollment in the phase 1 trial of GDC-0449. He did not meet enrollment criteria owing to the hematologic abnormalities. The pancytopenia was thought to be consistent with extensive marrow involvement. No clinically significant hematologic toxic effects had been observed in the clinical trials of GDC-0449 up to that time. Because of the lack of alternative therapies and the preclinical evidence that hedgehog signaling may be critical in medulloblastoma, a protocol deviation was proposed to allow this patient to be treated with GDC-0449. The protocol deviation was approved by the institutional review board at Johns Hopkins University on April 18, 2008, and the patient provided written informed consent.
Results
The patient received a single oral dose of 540 mg of GDC-0449 on April 22, 2008, followed 1 week later by initiation of daily dosing at 540 mg per day. The delay in the initiation of daily dosing was to allow for pharmacokinetic analyses of a single dose. Over the course of the week after administration of the single dose, his pain increased from 5 on the 10-point scale to 8; the pain was primarily localized in the shoulders. A magnetic resonance imaging (MRI) scan on April 25, 2008, showed matted right supraclavicular lymphadenopathy and an epidural mass at C7, with impending compression of the thecal sac (Figure 3A and 3B in the Supplementary Appendix). The patient refused to undergo further spinal surgery. Dexamethasone therapy, at a dose of 4 mg twice a day, was started for the management of pain; he received dexamethasone throughout the remainder of his treatment with GDC-0449. The pain lessened over the next 3 days, and the need for oxycodone decreased from a dose of up to 640 mg daily to 320 mg daily.
The patient began receiving 540 mg of GDC-0449 per day on April 29, 2008. On May 19, 2008, the supraclavicular lymphadenopathy and one of two sternal masses were no longer palpable; the other sternal mass was noted by the treating physician to have decreased in size, and he had no pain (0 on the 10-point scale). On June 23, 2008, he had no palpable nodules, continued to have a pain score of 0, and had returned to his normal level of activity. The physical examination was notable for weight gain — from 60 kg at baseline to 67 kg — and the absence of any palpable tumor. The pancytopenia persisted (total white cells, 960 per cubic millimeter; hemoglobin level, 9.3 g per deciliter; and platelets, 10,000 per cubic millimeter). A PET scan revealed marked diminution of 18F-fluorodeoxyglucose (FDG) avidity at all prior sites of disease (Figure 1B). Measurable disease noted previously, including the supraclavicular lymphadenopathy, was markedly diminished (Figure 3A and 3C in the Supplementary Appendix). The previously noted epidural mass at C7 was no longer detectable (Figure 3B and Figure 3D in the Supplementary Appendix). Over the course of the treatment with GDC-0449, the requirement for platelet transfusions decreased from twice a week to once a week. On July 23, 2008, approximately 3 months after the initiation of therapy with GDC-0449, a confirmatory restaging study was performed; the results indicated a continued response of some lesions but a marked increase in PET activity for several existing and new lesions (Figure 1C) and evidence of tumor regrowth at some sites (Figure 3E and 3F in the Supplementary Appendix). The patient was removed from the phase 1 study because of progression of the disease. During the time he was in the study, no adverse events higher than grade 1 that were related to treatment with GDC-0449 were reported. The disease progressed rapidly, despite a series of subsequent therapies, and the patient died on September 23, 2008.
Transcriptional profiling of medulloblastoma for hedgehog pathway target genes has been shown to accurately predict the presence of hedgehog pathway mutations.15 A biopsy specimen of the patient's metastatic tumor obtained before the initiation of GDC-0449 therapy was evaluated for markers of hedgehog pathway activation. Pathway activation by SMO leads to transcription of downstream target genes, including GLI family zinc finger 1 (GLI1), PTCH1, patched homologue 2 (PTCH2), and secreted frizzled-related protein 1 (SFRP1). Expression of these target genes in this patient's tumor was compared with the expression in a panel of 55 archival medulloblastoma samples by means of quantitative reverse-transcriptase–polymerase-chain-reaction (RT-PCR) (see Methods in the Supplementary Appendix). Expression of all four genes was in the upper 20% of all tumors evaluated, a finding that was suggestive of active hedgehog pathway signaling (Figure 2AFigure 2
Tumor-Specific Hedgehog Pathway Activation., and Figure 2 in the Supplementary Appendix). Genomic analysis of the PTCH1 locus in tumor cells was consistent with loss of heterozygosity and a single nucleotide substitution in exon 15 causing a W→C amino acid change at position 844 (Figure 2B; for further details, see Methods in the Supplementary Appendix). Somatic mutations in the same exon, encoding the second extracellular loop domain of PTCH1, have been described previously and are summarized in the PTCH mutation database (http://www.cybergene.se/cgi-bin/w3-msql/ptchbase/index.html). DNA from a biopsy specimen of normal skin revealed a wild-type sequence and no loss of heterozygosity, confirming that these alterations were somatic (Figure 2B). Sequencing of genes encoding other members of the hedgehog pathway revealed no nonsynonymous sequence alterations in suppressor of fused homologue (SuFu) or SMO (data not shown).Discussion
We describe a patient with advanced medulloblastoma that had been refractory to multiple prior therapies. The tumor had a remarkable, although incomplete, and rapid, although transient, response to inhibition of the hedgehog pathway with GDC-0449. To our knowledge, this report marks the first demonstration that an inhibitor of the hedgehog pathway can cause regression of medulloblastoma. The regression is notable because of the tumor burden and the extent of metastasis in this patient, with substantial soft-tissue and bony-tissue involvement and clinically significant bone marrow compromise, and underscores the primary role that the hedgehog pathway played in maintaining and driving the growth of this patient's tumor.
Our observation can be placed within the larger context of recent progress in cancer treatment involving targeted inhibitors of mutant signaling pathways. Frequently cited examples of targeting tumor-specific mutations include the use of imatinib in patients with chronic myelogenous leukemia and gastrointestinal stromal tumors, and the use of erlotinib in patients with non–small-cell lung cancer.16-18 In these examples, targeted inhibition of mutant and dysfunctional tyrosine kinases that have been implicated in the development, proliferation, and survival of tumor cells leads to remarkable antitumor responses. The case we describe represents a variation on this theme: a small-molecule inhibitor that targets an intact signaling factor (SMO), which is the primary target of a mutated and dysfunctional tumor suppressor (PTCH1).
A minority of medulloblastoma tumors are thought to harbor PTCH1 mutations or to be driven in some other way by hedgehog pathway signaling.19 The development of a diagnostic marker for hedgehog pathway activation has been challenging because alteration of many pathway components may result in an activated phenotype. On the basis of a recently published gene-expression signature that appears to correlate with hedgehog pathway activation in medulloblastoma,15 this patient's tumor showed specific pathway activation. Testing this and other potential strategies for identifying biomarkers will be important components of future clinical trials of hedgehog pathway inhibitors.
Even complete or near-complete responses to imatinib and erlotinib may not be durable. Multiple mechanisms of acquired resistance have been described, including secondary mutations in the kinase targets and up-regulation of alternative tyrosine kinases.20-23 Similarly, after initial marked regression, the tumor in our patient rapidly acquired resistance. Identifying the mechanisms of acquired resistance to selective hedgehog pathway inhibitors in patients with medulloblastoma will be of particular interest in future studies.
The use of a targeted inhibitor of a pathway that is clearly implicated in malignant transformation in medulloblastoma may offer a more effective therapeutic option than treatments that are currently available and may avoid some of their adverse effects. The hedgehog pathway regulates many developmental processes. Although an acceptable side-effect profile has been observed in an initial cohort of adults, it is unclear what the adverse effects of hedgehog pathway blockade may be in prepubescent children. Skeletal growth complications, including effects on both cartilage and bone formation, may limit the use of these therapies in young children.24 Cautious application of these initial observations through carefully monitored clinical trials involving a broad spectrum of patients with medulloblastoma is warranted.
Supported by Genentech. GDC-0449 was developed under a collaborative agreement between Genentech and Curis. Genentech and Roche collaborate on the clinical development of GDC-0449. Also supported by a Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund (to Dr. Rudin).
Drs. Rudin, Von Hoff, and LoRusso report receiving research funding from Genentech for a GDC-0449 phase 1 trial; Dr. Rudin, receiving a BioOncology Grant Program Award from Genentech; Dr. Laterra, receiving a consulting fee from Genentech; Dr. LoRusso, receiving lecture fees from Genentech; Drs. Yauch, Callahan, Fu, Gould, Holcomb, Stinson, de Sauvage, and Low, being employees of Genentech; and Dr. de Sauvage, holding patents in the area of hedgehog signaling. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0902903) was published on September 2, 2009, at NEJM.org.
We thank Dr. Richard Gilbertson for advice and discussion on molecular profiling of medulloblastoma.
Source Information
From the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore (C.M.R., C.L.H., J.L., B.C.); Genentech, South San Francisco, CA (R.L.Y., C.A.C., L.F., T.H., J.S., S.E.G., F.J.S., J.A.L.); Karmanos Cancer Institute, Wayne State University, Detroit (P.M.L.); and Translational Genomics (TGen), Scottsdale Clinical Research Institute, Scottsdale, AZ (D.D.V.H.).
Address reprint requests to Dr. Rudin at Johns Hopkins University, David H. Koch Cancer Research Bldg., Rm. 544, 1550 Orleans St., Baltimore, MD 21231, or at rudin@jhmi.edu.
- References
References
1
Crawford JR ,MacDonald TJ ,Packer RJ . Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007;6:1073-1085
CrossRef | Web of Science | Medline2
Zeltzer PM ,Boyett JM ,Finlay JL , et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-845
Web of Science | Medline3
Ingham PW ,Placzek M . Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 2006;7:841-850
CrossRef | Web of Science | Medline4
Fan X ,Eberhart CG . Medulloblastoma stem cells. J Clin Oncol 2008;26:2821-2827
CrossRef | Web of Science | Medline5
Wechsler-Reya RJ ,Scott MP . Control of neuronal precursor proliferation in the cerebellum by Sonic hedgehog. Neuron 1999;22:103-114
CrossRef | Web of Science | Medline6
Kenney AM ,Rowitch DH . Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol Cell Biol 2000;20:9055-9067
CrossRef | Web of Science | Medline7
Goodrich LV ,Milenkovic L ,Higgins KM ,Scott MP . Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997;277:1109-1113
CrossRef | Web of Science | Medline8
Oliver TG ,Read TA ,Kessler JD , et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development 2005;132:2425-2439
CrossRef | Web of Science | Medline9
Berman DM ,Karhadkar SS ,Hallahan AR , et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559-1561
CrossRef | Web of Science | Medline10
Romer JT ,Kimura H ,Magdaleno S , et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−)p53(−/−) mice. Cancer Cell 2004;6:229-240
CrossRef | Web of Science | Medline11
Lee Y ,Miller HL ,Jensen P , et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003;63:5428-5437
Web of Science | Medline12
Cowan R ,Hoban P ,Kelsey A ,Birch JM ,Gattamaneni R ,Evans DG . The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 1997;76:141-145
CrossRef | Web of Science | Medline13
Rudin CM ,Von Hoff DD ,LoRusso PM , et al. Updated safety and efficacy data from a first-in-human, first-in-class phase I study of Hedgehog pathway antagonist GDC-0449. Eur J Cancer 2008;6:112-11214
Von Hoff DD ,LoRusso PM ,Rudin CM , et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-1172
Full Text | Web of Science | Medline15
Thompson MC ,Fuller C ,Hogg TL , et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24:1924-1931
CrossRef | Web of Science | Medline16
Druker BJ ,Guilhot F ,O'Brien SG , et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417
Full Text | Web of Science | Medline17
Heinrich MC ,Corless CL ,Demetri GD , et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349
CrossRef | Web of Science | Medline18
Janne PA ,Engelman JA ,Johnson BE . Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234
CrossRef | Web of Science | Medline19
Gilbertson RJ ,Ellison DW . The origins of medulloblastoma subtypes. Annu Rev Pathol 2008;3:341-365
CrossRef | Web of Science | Medline20
Sequist LV ,Bell DW ,Lynch TJ ,Haber DA . Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-595
CrossRef | Web of Science | Medline21
Bean J ,Brennan C ,Shih JY , et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-20937
CrossRef | Web of Science | Medline22
Engelman JA ,Zejnullahu K ,Mitsudomi T , et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043
CrossRef | Web of Science | Medline23
Kantarjian HM ,Talpaz M ,Giles F ,O'Brien S ,Cortes J . New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-923
Web of Science | Medline24
Kimura H ,Ng JM ,Curran T . Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 2008;13:249-260
CrossRef | Web of Science | Medline
- Citing Articles (129)
Citing Articles
1
Zeshaan A Rasheed, William Matsui. (2012) Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. Journal of Gastroenterology and Hepatology 27, 15-18
CrossRef2
Jasmine Lau, Christin Schmidt, Shirley L. Markant, Michael D. Taylor, Robert J. Wechsler-Reya, William A. Weiss. (2012) Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Child's Nervous System
CrossRef3
Markus Eberl, Stefan Klingler, Doris Mangelberger, Andrea Loipetzberger, Helene Damhofer, Kerstin Zoidl, Harald Schnidar, Hendrik Hache, Hans-Christian Bauer, Flavio Solca, Cornelia Hauser-Kronberger, Alexandre N. Ermilov, Monique E. Verhaegen, Christopher K. Bichakjian, Andrzej A. Dlugosz, Wilfried Nietfeld, Maria Sibilia, Hans Lehrach, Christoph Wierling, Fritz Aberger. (2012) Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Molecular Medicinen/a-n/a
CrossRef4
Maria Kasper, Viljar Jaks, Daniel Hohl, Rune Toftgård. (2012) Basal cell carcinoma — molecular biology and potential new therapies. Journal of Clinical Investigation 122:2, 455-463
CrossRef5
K Kudo, E Gavin, S Das, L Amable, L A Shevde, E Reed. (2012) Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum–DNA adduct repair. Oncogene
CrossRef6
Antonio Solinas, Hélène Faure, Hermine Roudaut, Elisabeth Traiffort, Angèle Schoenfelder, André Mann, Fabrizio Manetti, Maurizio Taddei, Martial Ruat. (2012) Acylthiourea, Acylurea and Acylguanidine Derivatives with potent Hedgehog inhibiting Activity. Journal of Medicinal Chemistry120123154015009
CrossRef7
Ryan R. Hurtado, Allison S. Harney, Marie C. Heffern, Robert J. Holbrook, Robert A. Holmgren, Thomas J. Meade. (2012) Specific Inhibition of the Transcription Factor Ci by a Cobalt(III) Schiff Base–DNA Conjugate. Molecular Pharmaceutics120120104229003
CrossRef8
Tobias Kiesslich, Daniel Neureiter. (2012) Advances in targeting the Hedgehog signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets1-6
CrossRef9
Pamela Jo Harris, Giovanna Speranza, Claudio Dansky Ullmann. (2012) Targeting embryonic signaling pathways in cancer therapy. Expert Opinion on Therapeutic Targets 16:1, 131-145
CrossRef10
Yiwei Li, Ma'in Y Maitah, Aamir Ahmad, Dejuan Kong, Bin Bao, Fazlul H Sarkar. (2012) Targeting the Hedgehog signaling pathway for cancer therapy. Expert Opinion on Therapeutic Targets 16:1, 49-66
CrossRef11
Anita Villani, David Malkin, Uri Tabori. (2011) Syndromes Predisposing to Pediatric Central Nervous System Tumors: Lessons Learned and New Promises. Current Neurology and Neuroscience Reports
CrossRef12
Michael D. Taylor, Paul A. Northcott, Andrey Korshunov, Marc Remke, Yoon-Jae Cho, Steven C. Clifford, Charles G. Eberhart, D. Williams Parsons, Stefan Rutkowski, Amar Gajjar, David W. Ellison, Peter Lichter, Richard J. Gilbertson, Scott L. Pomeroy, Marcel Kool, Stefan M. Pfister. (2011) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica
CrossRef13
Jeffrey D. Winkler, André K. Isaacs, Chaomei Xiang, Valérie Baubet, Nadia Dahmane. (2011) Design, synthesis, and biological evaluation of estrone-derived hedgehog signaling inhibitors. Tetrahedron 67:52, 10261-10266
CrossRef14
Jean Y. Tang. (2011) Elucidating the Role of Molecular Signaling Pathways in the Tumorigenesis of Basal Cell Carcinoma. Seminars in Cutaneous Medicine and Surgery 30:4, S6-S9
CrossRef15
Kieren D. Marini, Brendan J. Payne, D. Neil Watkins, Luciano G. Martelotto. (2011) Mechanisms of Hedgehog signalling in cancer. Growth Factors 29:6, 221-234
CrossRef16
Tareq Al Baghdadi, Rafat Abonour, H. Scott Boswell. (2011) Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells. Clinical Lymphoma Myeloma and Leukemia
CrossRef17
Cristina Nay Fellay, Didier Frappaz, Marie P. Sunyach, Enrico Franceschi, Alba A. Brandes, Roger Stupp. (2011) Medulloblastomas in adults. Current Opinion in Neurology 24:6, 626-632
CrossRef18
Joel W. Neal, Matthew A. Gubens, Heather A. Wakelee. (2011) Current Management of Small Cell Lung Cancer. Clinics in Chest Medicine 32:4, 853-863
CrossRef19
Joseph G. Pressey, James R. Anderson, David K. Crossman, James C. Lynch, Frederic G. Barr. (2011) Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer 57:6, 930-938
CrossRef20
Jean Y. Tang, Ashfaq A. Marghoob. (2011) Emerging Treatments and Signaling Pathway Inhibitors. Seminars in Cutaneous Medicine and Surgery 30:4, S14-S18
CrossRef21
Eamon Berge, Chris Thompson, Wells Messersmith. (2011) Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer 10:4, 266-278
CrossRef22
Martial Ruat, Hermine Roudaut, Julien Ferent, Elisabeth Traiffort. (2011) Hedgehog trafficking, cilia and brain functions. Differentiation
CrossRef23
S. Fulda. (2011) Molekular zielgerichtete Krebstherapien bei Tumoren im Kindesalter. Der Onkologe 17:11, 1045-1051
CrossRef24
Steve S. Choi, Shelton Bradrick, Guan Qiang, Anahita Mostafavi, Gaurav Chaturvedi, Steven A. Weinman, Anna Mae Diehl, Ravi Jhaveri. (2011) Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. Hepatology 54:5, 1580-1590
CrossRef25
Franck Bourdeaut, Catherine Miquel, Claire Alapetite, Thomas Roujeau, Francois Doz. (2011) Medulloblastomas. Current Opinion in Oncology 23:6, 630-637
CrossRef26
Vijay Ramaswamy, Paul A. Northcott, Michael D. Taylor. (2011) FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genetics 204:11, 577-588
CrossRef27
B G Mar, D Amakye, I Aifantis, S Buonamici. (2011) The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia 25:11, 1665-1673
CrossRef28
Philippe A Cassier, Sana Intidhar Labidi-Galy, Pierre Heudel, Aurélie Dutour, Pierre Méeus, Maria Chelghoum, Laurent Alberti, Isabelle Ray-Coquard, Jean-Yves Blay. (2011) Therapeutic pipeline for soft-tissue sarcoma. Expert Opinion on Pharmacotherapy 12:16, 2479-2491
CrossRef29
Julia Izrailit, Michael Reedijk. (2011) Developmental pathways in breast cancer and breast tumor-initiating cells: Therapeutic implications. Cancer Letters
CrossRef30
Kwon-Sik Park, Luciano G Martelotto, Martin Peifer, Martin L Sos, Anthony N Karnezis, Moe R Mahjoub, Katie Bernard, Jamie F Conklin, Anette Szczepny, Jing Yuan, Ribo Guo, Beatrice Ospina, Jeanette Falzon, Samara Bennett, Tracey J Brown, Ana Markovic, Wendy L Devereux, Cory A Ocasio, James K Chen, Tim Stearns, Roman K Thomas, Marion Dorsch, Silvia Buonamici, D Neil Watkins, Craig D Peacock, Julien Sage. (2011) A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine 17:11, 1504-1508
CrossRef31
Hideya Onishi, Mitsuo Katano. (2011) Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Science 102:10, 1756-1760
CrossRef32
Jennifer M. Atkinson, Anang A. Shelat, Angel Montero Carcaboso, Tanya A. Kranenburg, Leggy A. Arnold, Nidal Boulos, Karen Wright, Robert A. Johnson, Helen Poppleton, Kumarasamypet M. Mohankumar, Clementine Féau, Timothy Phoenix, Paul Gibson, Liqin Zhu, Yiai Tong, Chris Eden, David W. Ellison, Waldemar Priebe, Dimpy Koul, W. K. Alfred Yung, Amar Gajjar, Clinton F. Stewart, R. Kiplin Guy, Richard J. Gilbertson. (2011) An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma. Cancer Cell 20:3, 384-399
CrossRef33
Matthew L. Brown, Wade Aaron, Richard J. Austin, Angela Chong, Tom Huang, Ben Jiang, Jacob A. Kaizerman, Gary Lee, Brian S. Lucas, Dustin L. McMinn, Jessica Orf, Minqing Rong, Maria M. Toteva, Guifen Xu, Qiuping Ye, Wendy Zhong, Michael R. DeGraffenreid, Dineli Wickramasinghe, Jay P. Powers, Randall Hungate, Michael G. Johnson. (2011) Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hit. Bioorganic & Medicinal Chemistry Letters 21:18, 5206-5209
CrossRef34
Ian F. Pollack. (2011) Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. Journal of Neurosurgery: Pediatrics 8:2, 135-148
CrossRef35
Inna V. Fedorenko, Kim H.T. Paraiso, Keiran S.M. Smalley. (2011) Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochemical Pharmacology 82:3, 201-209
CrossRef36
Murielle Mimeault, Surinder K. Batra. (2011) Complex Oncogenic Signaling Networks Regulate Brain Tumor-Initiating Cells and Their Progenies: Pivotal Roles of Wild-Type EGFR, EGFRvIII Mutant and Hedgehog Cascades and Novel Multitargeted Therapies. Brain Pathologyno-no
CrossRef37
Paul A. Northcott, Thomas Hielscher, Adrian Dubuc, Stephen Mack, David Shih, Marc Remke, Hani Al-Halabi, Steffen Albrecht, Nada Jabado, Charles G. Eberhart, Wieslawa Grajkowska, William A. Weiss, Steven C. Clifford, Eric Bouffet, James T. Rutka, Andrey Korshunov, Stefan Pfister, Michael D. Taylor. (2011) Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathologica 122:2, 231-240
CrossRef38
Chengxin Li, Sumin Chi, Jingwu Xie. (2011) Hedgehog signaling in skin cancers. Cellular Signalling 23:8, 1235-1243
CrossRef39
Hans Skvara, Frank Kalthoff, Josef G Meingassner, Barbara Wolff-Winiski, Heinrich Aschauer, Joseph F Kelleher, Xu Wu, Shifeng Pan, Lesanka Mickel, Christopher Schuster, Georg Stary, Ahmad Jalili, Olivier J David, Corinne Emotte, Ana Monica Costa Antunes, Kristine Rose, Jeremy Decker, Ilene Carlson, Humphrey Gardner, Anton Stuetz, Arthur P Bertolino, Georg Stingl, Menno A De Rie. (2011) Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor. Journal of Investigative Dermatology 131:8, 1735-1744
CrossRef40
Ian F. Pollack, Regina I. Jakacki. (2011) Childhood brain tumors: epidemiology, current management and future directions. Nature Reviews Neurology 7:9, 495-506
CrossRef41
Roberto Scatena, Patrizia Bottoni, Alessandro Pontoglio, Bruno Giardina. (2011) Cancer stem cells: the development of new cancer therapeutics. Expert Opinion on Biological Therapy 11:7, 875-892
CrossRef42
David A Reardon, James R Perry, Alba A Brandes, Rakesh Jalali, Wolfgang Wick. (2011) Advances in malignant glioma drug discovery. Expert Opinion on Drug Discovery 6:7, 739-753
CrossRef43
Ching-Hon Pui, Amar J. Gajjar, Javier R. Kane, Ibrahim A. Qaddoumi, Alberto S. Pappo. (2011) Challenging issues in pediatric oncology. Nature Reviews Clinical Oncology 8:9, 540-549
CrossRef44
Hideya Onishi, Masaya Kai, Seiichi Odate, Hironori Iwasaki, Yoshihiro Morifuji, Toshitatsu Ogino, Takafumi Morisaki, Yutaka Nakashima, Mitsuo Katano. (2011) Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Science 102:6, 1144-1150
CrossRef45
Guillaume Guerlet, Thomas Spangenberg, André Mann, Hélène Faure, Martial Ruat. (2011) Synthesis and biological evaluation of desmethylveramiline, a micromolar Hedgehog inhibitor. Bioorganic & Medicinal Chemistry Letters 21:12, 3608-3612
CrossRef46
M. Schlaak, W. Bartenwerffer, C. Mauch. (2011) Medikamentöse Therapie nichtmelanozytärer epithelialer Tumore. Der Hautarzt 62:6, 430-435
CrossRef47
Zeshaan A. Rasheed, Jeanne Kowalski, B. Douglas Smith, William Matsui. (2011) Concise Review: Emerging Concepts in Clinical Targeting of Cancer Stem Cells. STEM CELLS 29:6, 883-887
CrossRef48
Jason S. Rockel, Benjamin A. Alman. (2011) Don't hedge your bets: Hedgehog signaling as a central mediator of endochondral bone development and cartilage diseases. Journal of Orthopaedic Research 29:6, 810-815
CrossRef49
Yuzhong Deng, Harvey Wong, Richard A. Graham, Wenbin Liu, Heuy-shin Shen, Yao Shi, Laixin Wang, Min Meng, Vikram Malhi, Xiao Ding, Brian Dean. (2011) Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry. Journal of Chromatography B
CrossRef50
Jessica M. Y. Ng, Tom Curran. (2011) The Hedgehog's tale: developing strategies for targeting cancer. Nature Reviews Cancer 11:7, 493-501
CrossRef51
Elie Dolgin. (2011) Companies race to develop first Hedgehog inhibitor cancer drug. Nature Medicine 17:5, 523-523
CrossRef52
Yoshinari Asaoka, Tsuneo Ikenoue, Kazuhiko Koike. (2011) New targeted therapies for gastric cancer. Expert Opinion on Investigational Drugs 20:5, 595-604
CrossRef53
L. Taillandier, M. Blonski, C. Carrie, V. Bernier, F. Bonnetain, F. Bourdeaut, I.-C. Thomas, P. Chastagner, F. Dhermain, F. Doz, D. Frappaz, J. Grill, R. Guillevin, A. Idbaih, A. Jouvet, C. Kerr, F.-L. Donadey, L. Padovani, J. Pallud, M.-P. Sunyach. (2011) Les médulloblastomes : revue générale. Revue Neurologique 167:5, 431-448
CrossRef54
Lida A. Mina, George W. Sledge. (2011) Rethinking the metastatic cascade as a therapeutic target. Nature Reviews Clinical Oncology
CrossRef55
F. C. Kelleher. (2011) Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 32:4, 445-451
CrossRef56
Lucia Di Marcotullio, Gianluca Canettieri, Paola Infante, Azzura Greco, Alberto Gulino. (2011) Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1815:2, 241-252
CrossRef57
Haiyan Tao, Qihui Jin, Dong-In Koo, Xuebin Liao, Nathan P. Englund, Yan Wang, Arun Ramamurthy, Peter G. Schultz, Marion Dorsch, Joseph Kelleher, Xu Wu. (2011) Small Molecule Antagonists in Distinct Binding Modes Inhibit Drug-Resistant Mutant of Smoothened. Chemistry & Biology 18:4, 432-437
CrossRef58
Yee Hong Chia, Cynthia X. Ma. (2011) Hedgehog Pathway Inhibitors: Potential Applications in Breast Cancer. Current Breast Cancer Reports 3:1, 15-23
CrossRef59
David W. Ellison, James Dalton, Mehmet Kocak, Sarah Leigh Nicholson, Charles Fraga, Geoff Neale, Anna M. Kenney, Dan J. Brat, Arie Perry, William H. Yong, Roger E. Taylor, Simon Bailey, Steven C. Clifford, Richard J. Gilbertson. (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica 121:3, 381-396
CrossRef60
F. Li, W. Shi, M. Capurro, J. Filmus. (2011) Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. The Journal of Cell Biology 192:4, 691-704
CrossRef61
Michael E. Dodge, Lawrence Lum. (2011) Drugging the Cancer Stem Cell Compartment: Lessons Learned from the Hedgehog and Wnt Signal Transduction Pathways. Annual Review of Pharmacology and Toxicology 51:1, 289-310
CrossRef62
Joel W Neal, Matthew A Gubens, Heather A Wakelee. (2011) Emerging treatments for small-cell lung cancer: Phase II and III trials. Clinical Investigation 1:2, 255-263
CrossRef63
Hani Al-Halabi, Andre Nantel, Almos Klekner, Marie-Christine Guiot, Steffen Albrecht, Peter Hauser, Miklos Garami, Laszlo Bognar, Peter Kavan, Noha Gerges, Margret Shirinian, David Roberge, Thierry Muanza, Nada Jabado. (2011) Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. Acta Neuropathologica 121:2, 229-239
CrossRef64
Boyan K. Garvalov, Till Acker. (2011) Cancer stem cells: a new framework for the design of tumor therapies. Journal of Molecular Medicine 89:2, 95-107
CrossRef65
G. Praveen Raju. (2011) Arsenic: a potentially useful poison for Hedgehog-driven cancers. Journal of Clinical Investigation 121:1, 14-16
CrossRef66
Elspeth M. Beauchamp, Lymor Ringer, Gülay Bulut, Kamal P. Sajwan, Michael D. Hall, Yi-Chien Lee, Daniel Peaceman, Metin Özdemirli, Olga Rodriguez, Tobey J. Macdonald, Chris Albanese, Jeffrey A. Toretsky, Aykut Üren. (2011) Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. Journal of Clinical Investigation 121:1, 148-160
CrossRef67
Rosamaria Lappano, Marcello Maggiolini. (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. Nature Reviews Drug Discovery 10:1, 47-60
CrossRef68
Malcolm R Alison, Susan ML Lim, Linda J Nicholson. (2011) Cancer stem cells: problems for therapy?. The Journal of Pathology 223:2, 148-162
CrossRef69
Stephanie Clayton, Shaker A Mousa. (2011) Therapeutics formulated to target cancer stem cells: Is it in our future?. Cancer Cell International 11:1, 7
CrossRef70
Fatima Rangwala, Alessia Omenetti, Anna Mae Diehl. (2011) Cancer Stem Cells: Repair Gone Awry?. Journal of Oncology 2011, 1-11
CrossRef71
Tomoyo Sakata, James K. Chen. (2011) Chemical ‘Jekyll and Hyde’s: small-molecule inhibitors of developmental signaling pathways. Chemical Society Reviews 40:8, 4318
CrossRef72
M.B. Karpova, M.J. Barysch, M.C. Zipser, N. Schönewolf, L.E. French, R. Dummer. (2011) Changing Pathology with Changing Drugs: Skin Cancer. Pathobiology 78:2, 61-75
CrossRef73
Matthias Lauth, Rune Toftgård. 2011. Hedgehog Signaling and Pancreatic Tumor Development. , 1-17.
CrossRef74
Stephan R. Bohl, Andreas Pircher, Wolfgang Hilbe. (2011) Cancer Stem Cells: Characteristics and Their Potential Role for New Therapeutic Strategies. Onkologie 34:5, 269-274
CrossRef75
Seung Lee, Candice Krauthauser, Victoria Maduskuie, Paul T Fawcett, James M Olson, Sigrid A Rajasekaran. (2011) Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 11:1, 144
CrossRef76
Pietro Ferruzzi, Federica Mennillo, Antonella De Rosa, Cinzia Giordano, Marco Rossi, Giovanni Benedetti, Roberta Magrini, Gal.la Pericot Mohr, Vincenzo Miragliotta, Letizia Magnoni, Elisa Mori, Russell Thomas, Patrizia Tunici, Annette Bakker. (2011) In vitro and in vivo characterization of a novel hedgehog signaling antagonist in human glioblastoma cell lines. International Journal of Cancern/a-n/a
CrossRef77
Paul Gibson, Yiai Tong, Giles Robinson, Margaret C. Thompson, D. Spencer Currle, Christopher Eden, Tanya A. Kranenburg, Twala Hogg, Helen Poppleton, Julie Martin, David Finkelstein, Stanley Pounds, Aaron Weiss, Zoltan Patay, Matthew Scoggins, Robert Ogg, Yanxin Pei, Zeng-Jie Yang, Sonja Brun, Youngsoo Lee, Frederique Zindy, Janet C. Lindsey, Makoto M. Taketo, Frederick A. Boop, Robert A. Sanford, Amar Gajjar, Steven C. Clifford, Martine F. Roussel, Peter J. McKinnon, David H. Gutmann, David W. Ellison, Robert Wechsler-Reya, Richard J. Gilbertson. (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468:7327, 1095-1099
CrossRef78
A Zibat, E Missiaglia, A Rosenberger, K Pritchard-Jones, J Shipley, H Hahn, S Fulda. (2010) Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 29:48, 6323-6330
CrossRef79
Shivan H. Amin, Raoul Tibes, Ji-Eon Kim, C. Patrick Hybarger. (2010) Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. The Laryngoscope 120:12, 2456-2459
CrossRef80
Emmanuel S. Antonarakis, Michael A. Carducci. (2010) Future Directions in Castrate-Resistant Prostate Cancer Therapy. Clinical Genitourinary Cancer 8:1, 37-46
CrossRef81
Hiroko Ohgaki, Young-Ho Kim, Joachim P Steinbach. (2010) Nervous system tumors associated with familial tumor syndromes. Current Opinion in Neurology 23:6, 583-591
CrossRef82
Steven Ray Wilson, Martin Frank Strand, Andreas Krapp, Frode Rise, Gunnar Herstad, Karl Egil Malterud, Stefan Krauss. (2010) Hedgehog antagonists cyclopamine and dihydroveratramine can be mistaken for each other in Veratrum album. Journal of Pharmaceutical and Biomedical Analysis 53:3, 497-502
CrossRef83
Georgette M. Castanedo, Shumei Wang, Kirk D. Robarge, Elizabeth Blackwood, Daniel Burdick, Christine Chang, Gerrit J.P. Dijkgraaf, Stephen Gould, Janet Gunzner, Oivin Guichert, Jason Halladay, Cyrus Khojasteh, Leslie Lee, James C. Marsters, Lesley Murray, David Peterson, Emile Plise, Laurent Salphati, Frederic J. de Sauvage, Susan Wong, Daniel P. Sutherlin. (2010) Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway. Bioorganic & Medicinal Chemistry Letters 20:22, 6748-6753
CrossRef84
Stefan M. Pfister, Andrey Korshunov, Marcel Kool, Martin Hasselblatt, Charles Eberhart, Michael D. Taylor. (2010) Molecular diagnostics of CNS embryonal tumors. Acta Neuropathologica 120:5, 553-566
CrossRef85
Roger Stupp, Monika Hegi, Michael Weller. (2010) Neuro-oncology, a decade of temozolomide and beyond. Expert Review of Anticancer Therapy 10:11, 1675-1677
CrossRef86
Leopold Arko, Igor Katsyv, Grace E. Park, William Patrick Luan, John K. Park. (2010) Experimental approaches for the treatment of malignant gliomas. Pharmacology & Therapeutics 128:1, 1-36
CrossRef87
Meg R. Gerstenblith, Alisa M. Goldstein, Margaret A. Tucker. (2010) Hereditary Genodermatoses with Cancer Predisposition. Hematology/Oncology Clinics of North America 24:5, 885-906
CrossRef88
Sean P. McDermott, Max S. Wicha. (2010) Targeting breast cancer stem cells. Molecular Oncology 4:5, 404-419
CrossRef89
Tom Curran. (2010) Mouse models and mouse supermodels. EMBO Molecular Medicine 2:10, 385-386
CrossRef90
S. Buonamici, J. Williams, M. Morrissey, A. Wang, R. Guo, A. Vattay, K. Hsiao, J. Yuan, J. Green, B. Ospina, Q. Yu, L. Ostrom, P. Fordjour, D. L. Anderson, J. E. Monahan, J. F. Kelleher, S. Peukert, S. Pan, X. Wu, S.-M. Maira, C. Garcia-Echeverria, K. J. Briggs, D. N. Watkins, Y.-m. Yao, C. Lengauer, M. Warmuth, W. R. Sellers, M. Dorsch. (2010) Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma. Science Translational Medicine 2:51, 51ra70-51ra70
CrossRef91
David W. Ellison. (2010) Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica 120:3, 305-316
CrossRef92
Philipp Heretsch, Lito Tzagkaroulaki, Athanassios Giannis. (2010) Modulators of the hedgehog signaling pathway. Bioorganic & Medicinal Chemistry 18:18, 6613-6624
CrossRef93
S Kurita, J L Mott, L L Almada, S F Bronk, N W Werneburg, S-Y Sun, L R Roberts, M E Fernandez-Zapico, G J Gores. (2010) GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene 29:34, 4848-4858
CrossRef94
Jacob A. Kaizerman, Wade Aaron, Songzhu An, Richard Austin, Matt Brown, Angela Chong, Tom Huang, Randall Hungate, Ben Jiang, Michael G. Johnson, Gary Lee, Brian S. Lucas, Jessica Orf, Minqing Rong, Maria M. Toteva, Dineli Wickramasinghe, Guifen Xu, Qiuping Ye, Wendy Zhong, Dustin L. McMinn. (2010) Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines. Bioorganic & Medicinal Chemistry Letters 20:15, 4607-4610
CrossRef95
Rony Nehmé, Isabelle Mus-Veteau. (2010) Proteins of the Hedgehog signaling pathway as therapeutic targets against cancer. Expert Review of Proteomics 7:4, 601-612
CrossRef96
Jeremy F Reiter, Frederic J de Sauvage. (2010) Vive la science! Vive le hérisson!. EMBO reports 11:8, 566-568
CrossRef97
S. Z. Rush, T. W. Abel, J. G. Valadez, M. Pearson, M. K. Cooper. (2010) Activation of the Hedgehog pathway in pilocytic astrocytomas. Neuro-Oncology 12:8, 790-798
CrossRef98
J. Kim, J. J. Lee, J. Kim, D. Gardner, P. A. Beachy. (2010) Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proceedings of the National Academy of Sciences 107:30, 13432-13437
CrossRef99
Zhi Huang, Lin Cheng, Olga A. Guryanova, Qiulian Wu, Shideng Bao. (2010) Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting. Protein & Cell 1:7, 638-655
CrossRef100
Milena Saqui-Salces, Juanita L. Merchant. (2010) Hedgehog signaling and gastrointestinal cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1803:7, 786-795
CrossRef101
Judith V. M. G. Bovée, Pancras C. W. Hogendoorn, Jay S. Wunder, Benjamin A. Alman. (2010) Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nature Reviews Cancer 10:7, 481-488
CrossRef102
E Julian, R K Dave, J P Robson, A R Hallahan, B J Wainwright. (2010) Canonical Notch signaling is not required for the growth of Hedgehog pathway-induced medulloblastoma. Oncogene 29:24, 3465-3476
CrossRef103
K H T Paraiso, I V Fedorenko, L P Cantini, A C Munko, M Hall, V K Sondak, J L Messina, K T Flaherty, K S M Smalley. (2010) Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. British Journal of Cancer 102:12, 1724-1730
CrossRef104
Joel W. Neal, Lecia V. Sequist. (2010) Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh. Current Treatment Options in Oncology 11:1-2, 36-44
CrossRef105
Thomas Palm, Jens C. Schwamborn. (2010) Brain tumor stem cells. Biological Chemistry 391:6, 607-617
CrossRef106
Martin R Tremblay, Karen McGovern, Margaret A Read, Alfredo C Castro. (2010) New developments in the discovery of small molecule Hedgehog pathway antagonists. Current Opinion in Chemical Biology 14:3, 428-435
CrossRef107
G J Weiss, D D Von Hoff. (2010) Hunting the Hedgehog Pathway. Clinical Pharmacology & Therapeutics 87:6, 743-747
CrossRef108
Dezső Schuler. (2010) A kemoterápia szerepe a gyermekkori medulloblastoma kezelésében. Magyar Onkológia 54:2, 145-152
CrossRef109
Mitchell S. Cairo, Craig T. Jordan, Carlo C. Maley, Clifford Chao, Ari Melnick, Scott A. Armstrong, Warren Shlomchik, Jeff Molldrem, Soldano Ferrone, Crystal Mackall, Laurence Zitvogel, Michael R. Bishop, Sergio A. Giralt, Carl H. June. (2010) NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. Biology of Blood and Marrow Transplantation 16:6, 709-728
CrossRef110
Philipp Heretsch, Lito Tzagkaroulaki, Athanassios Giannis. (2010) Cyclopamine and Hedgehog Signaling: Chemistry, Biology, Medical Perspectives. Angewandte Chemie International Edition 49:20, 3418-3427
CrossRef111
Elisabeth Traiffort, Elodie Angot, Martial Ruat. (2010) Sonic Hedgehog signaling in the mammalian brain. Journal of Neurochemistry 113:3, 576-590
CrossRef112
Jörg Dietrich, Eli L Diamond, Santosh Kesari. (2010) Glioma stem cell signaling: therapeutic opportunities and challenges. Expert Review of Anticancer Therapy 10:5, 709-722
CrossRef113
Joana Monteiro, Riccardo Fodde. (2010) Cancer stemness and metastasis: Therapeutic consequences and perspectives. European Journal of Cancer 46:7, 1198-1203
CrossRef114
Stephen Leong, Wells A. Messersmith, Aik Choon Tan, S. Gail Eckhardt. (2010) Novel Agents in the Treatment of Metastatic Colorectal Cancer. The Cancer Journal 16:3, 273-282
CrossRef115
Stefan Peukert, Karen Miller-Moslin. (2010) Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics. ChemMedChem 5:4, 500-512
CrossRef116
Philipp Heretsch, Lito Tzagkaroulaki, Athanassios Giannis. (2010) Cyclopamin und der Hedgehog-Signaltransduktionsweg: Chemie, Biologie, medizinische Perspektiven. Angewandte ChemieNA-NA
CrossRef117
Fritz Aberger, M. Eberl. (2010) Stemming cancer by Hedgehog pathway inhibition: from flies to bedside. memo - Magazine of European Medical Oncology 3:1, 3-6
CrossRef118
James Kim, Jean Y. Tang, Ruoyu Gong, Jynho Kim, John J. Lee, Karl V. Clemons, Curtis R. Chong, Kris S. Chang, Mark Fereshteh, Dale Gardner, Tannishtha Reya, Jun O. Liu, Ervin H. Epstein, David A. Stevens, Philip A. Beachy. (2010) Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth. Cancer Cell 17:4, 388-399
CrossRef119
Laura J. Klesse, Daniel C. Bowers. (2010) Childhood Medulloblastoma. CNS Drugs 24:4, 285-301
CrossRef120
Monika L. Burness, Dorothy A. Sipkins. (2010) The stem cell niche in health and malignancy. Seminars in Cancer Biology 20:2, 107-115
CrossRef121
C. Hafner. (2010) Zielgerichtete medikamentöse Therapie des Basalzellkarzinoms durch Inhibition des Hedgehog-Signalwegs. Der Hautarzt 61:4, 356-358
CrossRef122
L Yang, G Xie, Q Fan, J Xie. (2010) Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29:4, 469-481
CrossRef123
S. J. Diede, J. Guenthoer, L. N. Geng, S. E. Mahoney, M. Marotta, J. M. Olson, H. Tanaka, S. J. Tapscott. (2010) From the Cover: DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proceedings of the National Academy of Sciences 107:1, 234-239
CrossRef124
Cormac Sheridan. (2009) Genentech obtains proof of concept for hedgehog inhibition. Nature Biotechnology 27:11, 968-969
CrossRef125
R. L. Yauch, G. J. P. Dijkgraaf, B. Alicke, T. Januario, C. P. Ahn, T. Holcomb, K. Pujara, J. Stinson, C. A. Callahan, T. Tang, J. F. Bazan, Z. Kan, S. Seshagiri, C. L. Hann, S. E. Gould, J. A. Low, C. M. Rudin, F. J. de Sauvage. (2009) Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma. Science 326:5952, 572-574
CrossRef126
Sarah Seton-Rogers. (2009) Therapeutic resistance: Smoothing the way. Nature Reviews Cancer 9:11, 768-769
CrossRef127
Monique T. Barakat, Matthew P. Scott. (2009) Tail Wags Dog: Primary Cilia and Tumorigenesis. Cancer Cell 16:4, 276-277
CrossRef128
Von Hoff, Daniel D., LoRusso, Patricia M., Rudin, Charles M., Reddy, Josina C., Yauch, Robert L., Tibes, Raoul, Weiss, Glen J., Borad, Mitesh J., Hann, Christine L., Brahmer, Julie R., Mackey, Howard M., Lum, Bertram L., Darbonne, Walter C., Marsters, James C. Jr., de Sauvage, Frederic J., Low, Jennifer A., . (2009) Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. New England Journal of Medicine 361:12, 1164-1172
Full Text129
Dlugosz, Andrzej A., Talpaz, Moshe, . (2009) Following the Hedgehog to New Cancer Therapies. New England Journal of Medicine 361:12, 1202-1205
Full Text
